(UroToday.com) PSMA-targeted radionuclide therapy (TRT) is one of the most promising investigational therapies in prostate cancer currently. In the phase II TheraP trial and the phase III VISION trial, 177-lutetium-PSMA-617 has demonstrated better outcomes compared to the current standard of care treatment options for patients who have received many lines of therapy for metastatic castration resistant prostate cancer (mCRPC). Both TheraP (PSMA-PET and FDG-PET) and VISION (PSMA-PET) have been used for patient selection. Further, to date, most studies have administered moderate radionuclide doses over cycles 6-10 weeks apart. However, dose-escalation is feasible and may be able to overcome treatment resistance due to repopulation.